Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Salmon calcitonin 100 MRCU/day or a saline placebo were given in daily injections for at least three months to 49 patients with bone metastases from breast cancer in a randomized double-blind trial. All patients were normocalcemic, and most patients had stable or regressing disease at start of trial. No improvement in general performance or bone pain was detected as measured by a visual analogue scale, the daily duration of pain or consumption of analgetic drugs. Calcitonin had no effect on disease progression as judged by bone scans and radiographs. Calcitonin therapy did not affect serum calcium, alkaline phosphatase, bone gla-protein, or the urinary excretion of calcium and hydroxyproline. Serum phosphate and magnesium decreased significantly during calcitonin treatment (p = 0.01, and 0.00005, respectively). It was concluded that salmon calcitonin in this dosage has no discernible effect on skeletal pain, general performance, bone metabolism or disease progression in patients with breast cancer metastatic to bone. A significant decrease in serum phosphate and magnesium probably indicated an effect of calcitonin on the renal excretion of these ions.
 ...
PMID:Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trial. 328 58

The most essential role of Miacalcic (Calcitonin Sandoz), a 32-amino-acids peptide, is the preservation of osseal integrity. Based on this physiological fact it is assumed that this hormone may have a bone-regenerating effect in bone metastasis formation and sometimes in other malignancies. Though no considerable calcium incorporation could be revealed in our 58 patient treated with Miacalcic, a marked relief of pain was observed in 65.5% of the patients. For objectivation of the subjective pain sensation, the decrease in the quantity of other analgetics used daily, duration of pain and changes of its intensity were studied. These figures were 35.4% on the average, from 12.5-6 h and 23.6%, respectively. The pain-killing character of Miacalcic cannot be explained, but the following assumptions are made: (1) it partially inhibits the synthesis of algogenous peptides; (2) with its possibly cytostatic effect it inhibits the cell proliferation in loco and normalizes the internal pressure of the destroyed region, and (3) by conversion into beta-endorphin it exerts its effect centrally. Compared to the pain-killing effect, the simultaneous improvement of the quality of life seems to be even more essential. It has been proved earlier that a hormone physiologically present, when applied in a high dose, has an analgetic effect, i.e. by utilizing the endogenous substance of the organism, relief of pain can be achieved. We should like to point out that Miacalcic is the only analgetic agent capable of ensuring relief of pain with a simultaneous improvement of the quality of life. Accordingly, the application of Miacalcic in patients suffering from malignant tumours is highly recommended.
 ...
PMID:Pain killing with calcitonin in patients with malignant tumours. 351 74

The authors report 6 cases of transient osteoporosis of the hip. This is a rare disease but it should nevertheless be taken into account in the differential diagnosis with other inflammatory or neoplastic diseases of the hip. Even without treatment, it tends to regress spontaneously, but the pain can sometimes last for several months. Calcitonin is a reliable therapeutic agent and considerably shortens the natural course of the disease.
 ...
PMID:Transient osteoporosis of the hip. 379 58

Using electrophysiological methods to detect the extracellular activity of single neurons in the thalamus of anaesthetized rats, their response to mechanical and thermal noxious stimuli were assessed before and after administration of 4 analgesic peptides of various types. Dermophin, a peptide extracted from frog's skin, was found to have an opioid-like antinociceptive activity antagonized by naloxone. Caerulein, which has a similar origin, failed to suppress the nociceptive responses of thalamic neurons evoked by peripheral stimuli. Calcitonin, a peptide found at brain level, induced an alteration of the increased firing characteristic of noxious stimuli, and its action was not reversed by naloxone. FK 33-824, a synthetic peptide, induced a morphine-like action when injected i.c.v. at a dosage 1000 times lower than that of morphine on a molar basis. It is concluded that electrophysiological investigations on peptides endowed with analgesic activity contribute greatly to a more precise profile of the peptides as candidate drugs in pain control.
 ...
PMID:Comparative study on the electrophysiological responses at thalamic level to different analgesic peptides. 400 78

Synthetic Calcitonin Derivative obtained from eel (eel-calcitonin) was given to 15 patients suffering from pain due to bone metastases of malignant tumors. The analgesic effect of synthetic eel-calcitonin derivative was evaluated through pain and narcotic score with the Ridit method. With regard to pain score, significant analgesic effect was observed in the first week (p less than 0.001), and after a month there was also a decrease in the narcotic score (p less than 0.05). However, changes in serum Ca, P, ALP values, and the findings of bone scintigrams and roentgenography, rarely occurred following the treatment. The toxicities of eel-calcitonin which were observed in this series were as follows; nausea and vomiting (33%), flush (11%), eruption (6%). These findings suggest that synthetic eel-calcitonin derivative is a very useful agent for pain due to bone metastases.
 ...
PMID:[Effect of treatment with synthetic eel-calcitonin derivative in patients suffering pain due to bone metastases]. 405 17

Synthetic human calcitonin was used in the treatment of 26 patients over a period of 1-14 months. 17 patients had Paget's disease of the bone, 6 postmenopausal osteoporosis and 3 Sudeck's syndrome. Subjective improvement (reduction of pain, improvement of mobility) was found in 15 patients with Paget's disease, in 4 females with postmenopausal osteoporosis and in all 3 patients with Sudeck's syndrome. Radiographic improvement of bone changes developed only very slowly. These results were confirmed by diminution of the exchangeable calcium pool indicating reduction of rates of osseous degradation. Calcitonin tolerance was acceptable. Transitory nausea and occasional vomiting occurred in 3 patients.
 ...
PMID:[Synthetic human calcitonin in Paget's disease of bone and osteoporosis (author's transl)]. 616 31

Forty-one patients with a possible diagnosis of neurogenic claudication were treated with Calcitonin for four weeks. Eleven responded with considerable improvement in their walking distance. Ten agreed to enter a randomized double-blind cross-over trial, and eight made a correct assessment. It is concluded that Calcitonin is effective in relieving symptoms of neurogenic claudication for some patients. Five patients have received the drug for over one year with no serious side effects, and two have not relapsed after discontinuing the drug. Patients likely to respond will probably have symptoms affecting both legs equally pain extending below the upper calf, limiting walking to under a mile; an abnormal myelogram; and no more than one inappropriate sign. They are more likely to be men in late middle age who have been engaged in manual work. The beneficial effect of Calcitonin is probably the result of an arterial shunt mechanism, whereby a reduction in skeletal blood flow provides for a deprived cauda equina.
 ...
PMID:Calcitonin treatment for neurogenic claudication. 635 71

Animal experiments demonstrate that the intracerebro-ventricular administration of calcitonin induces analgesia. During the treatment of such diseases as osteitis deformans Paget and acute pancreatitis with calcitonin no spectacular pain-relieving effect was evident, but the application of calcitonin in hypercalcemic patients with bone tumors led to considerable pain relief. Recent double-blind studies document the analgesic effectiveness of calcitonin in malignant diseases, but also against postoperative pains in nontumor patients. Calcitonin as an analgesic drug deserves further investigation.
 ...
PMID:Calcitonin: analgesic effects. 636 72

Infusion of 200 IU Calcitonin-Sandoz in 20 of 44 hospitalized patients with malignant tumor suffering from chronic severe pain due to bone metastases, reduced the intensity of pain and with it the need for analgesics for an average of 10 hours. The result points to an analgesic potential of salmon-calcitonin.
 ...
PMID:[Salmon calcitonin in metastatic bone pain. Demonstration of acute analgesia in tumor patients]. 637 42

Calcitonin obtained from eels (ell-CT) was given to 14 patients who had developed bony pains due to bone metastases of malignant tumors and who did not respond to 12 various analgesics. The patients consisted of 12 males and 2 females, with a mean age of sixty-five. Eel-CT (Elcitonin) was injected intramuscularly to each patient at a dose of 40 units twice daily. Other analgesics were assessed to be ineffective at the time of CT administration and they were not given consideration in the evaluation. For the assessment of drug effect, a pain score was prepared. Eel-CT was markedly effective in 3 patients, effective in 8 patients, and ineffective in 2 patients. Eel-CT had a better effect on prostatic cancer than any other cancer. The analgesic effect was observed in the first week of drug administration at around a total dose of 1,000 units. Although the pain tended to appear at regions on which the body weight was liable to rest, the analgesic effect was seen irrespective of the side of pain. Since serum calcium, phosphate, parathyroid hormone (PTH), CT levels and bone scintigrams between pre-and post-CT administration did not differ, the analgesic mode of action of CT is not supposed to be related to inhibition of bone absorption nor bone formation. The therapeutic effect hardly suggests any direct action of CT on the tumor.
 ...
PMID:[Effect of calcitonin on body pains caused by bone metastases of urogenital cancer]. 667 46


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>